News Posts List
Wilson wants cancer drug changes
03/05/2009
The son of the late broadcaster Tony Wilson is calling for a change in the NHS system which leaves dying patients fighting for drugs to keep themselves alive.
Simple Nomogram Risk-Stratifies Renal Cell Cancer Patients on Targeted Therapy
03/05/2009
"This model can be used to stratify patients on clinical trials and in clinical practice," said Dr. Heng.
Tumor suppressors may prompt cancer to return
03/04/2009
The drugs, which include Pfizer's Sutent and Genentech's top-selling Avastin, are designed to starve tumors by blocking the formation of new blood vessels that could nourish their growth.
Cancer miracles
03/04/2009
Spontaneous tumor regressions are among the rarest and most mysterious events in medicine,
UCLA launches new Institute of Urologic Oncology
03/04/2009
Team will deliver multidisciplinary care, develop leading-edge therapies, including treatment of renal cancers.
A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival
03/04/2009
Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources.
Motorcycle Cancer Risk
03/04/2009
Randall Dale Chipkar has a rider safety motorcycle cancer website with information about The Motorcycle Cancer Book, prostate cancer, colon cancer, and kidney cancer, among others.
Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patients with Advanced Kidney Cancer
03/04/2009
AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced positive interim results from a 272-patient Phase 2 clinical trial of AV-951, a novel, oral, triple VEGF receptor inhibitor, in patients with advanced renal cell carcinoma (RCC).
Reliable Indicators of Overall Survival
03/04/2009
Prognostic factors from the Memorial Sloan Kettering Cancer Center (MSKCC) model plus 2 additional factors are valid predictors of overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents.
Targeted Therapy Improves Survival in Poor-Risk Renal Cancer
03/04/2009
Patients with poor-risk renal cell carcinoma have improved survival with temsirolimus (Torisel) whether they have a nephrectomy or not.
News Feed